---
title: "Guotai Haitong Keeps Their Buy Rating on The United Laboratories International Holdings (ULIHF)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/282759624.md"
description: "Guotai Haitong has maintained a Buy rating on The United Laboratories International Holdings (ULIHF) with a price target of HK$15.53, while the shares closed at HK$9.80. The overall analyst consensus for the company is a Strong Buy, with an average price target of HK$16.36."
datetime: "2026-04-15T00:29:58.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/282759624.md)
  - [en](https://longbridge.com/en/news/282759624.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/282759624.md)
---

# Guotai Haitong Keeps Their Buy Rating on The United Laboratories International Holdings (ULIHF)

In a report released on April 13, from Guotai Haitong maintained a Buy rating on The United Laboratories International Holdings, with a price target of HK$15.53. The company’s shares closed yesterday at HK$9.80.

### Claim 30% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

The word on The Street in general, suggests a Strong Buy analyst consensus rating for The United Laboratories International Holdings with a HK$16.36 average price target.

### Related Stocks

- [03933.HK](https://longbridge.com/en/quote/03933.HK.md)
- [159316.CN](https://longbridge.com/en/quote/159316.CN.md)
- [159570.CN](https://longbridge.com/en/quote/159570.CN.md)
- [588250.CN](https://longbridge.com/en/quote/588250.CN.md)
- [513700.CN](https://longbridge.com/en/quote/513700.CN.md)
- [520690.CN](https://longbridge.com/en/quote/520690.CN.md)
- [520880.CN](https://longbridge.com/en/quote/520880.CN.md)
- [520500.CN](https://longbridge.com/en/quote/520500.CN.md)
- [512290.CN](https://longbridge.com/en/quote/512290.CN.md)
- [513120.CN](https://longbridge.com/en/quote/513120.CN.md)
- [560600.CN](https://longbridge.com/en/quote/560600.CN.md)
- [516820.CN](https://longbridge.com/en/quote/516820.CN.md)
- [159506.CN](https://longbridge.com/en/quote/159506.CN.md)
- [159992.CN](https://longbridge.com/en/quote/159992.CN.md)
- [588860.CN](https://longbridge.com/en/quote/588860.CN.md)

## Related News & Research

- [Analyst Reiterates Buy on Microbix, Citing Temporary China Slowdown and Growing Diversified Demand](https://longbridge.com/en/news/286665358.md)
- [SSY Group wins China NMPA approval for emedastine difumarate eye drops 0.05%](https://longbridge.com/en/news/287187916.md)
- [Shanghai Henlius says China regulator clears HLX48 Phase 1 trial IND for solid tumors](https://longbridge.com/en/news/287189347.md)
- [Everest Medicines Director and Major Shareholder Raises Stake in Company](https://longbridge.com/en/news/286481551.md)
- [Flow Pharma U.S. Patent Application Allowed for Issuance Covering Broad-Spectrum Ebola Therapy](https://longbridge.com/en/news/287076761.md)